BME100 s2014:W Group2 L2

From OpenWetWare

Jump to: navigation, search
BME 100 Fall 2013 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help
Image:BME494_Asu_logo.png

Contents

OUR TEAM

Name: Marianne Alnimri
Name: Marianne Alnimri
Name: Carilee Farrell
Name: Carilee Farrell
Name: Joel Larson
Name: Joel Larson
Name: Roger Rose
Name: Roger Rose
Name: Marshall Treleven
Name: Marshall Treleven

LAB 2 WRITE-UP

Descriptive Statistics

Experiment 1


Experiment 2




Results

Experiment 1


Experiment 2





Analysis

Experiment 1


Experiment 2




Summary/Discussion

Based on the ANOVA and post-hoc t-test we are able to determine that all of the data from the human study is significant. We chose to do a t-test for the comparison of the data in the rat experiment because there were only 2 different experimental groups. ANOVA was used for the comparison of the human data because there were 4 different experimental groups each receiving a different amount of LPS. For the human test, a significant difference was achieved comparing each dosage level of the LPS drug. More specifically, the difference between the 10mg dosage and the 15mg dosage was the most significant. For the rat study, the T-Test gave a P-value of .02268, which means there was a significant difference in the data between the two LPS dosage samples in rats. On average, for the rats, the dosage of LPS increases inflammotin levels just like it does in humans, however with humans there is a more dramatic increase of inflammotin levels when changing the dosage of LPS.

Personal tools